We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    03875651
Previous Study | Return to List | Next Study

A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03875651
Recruitment Status : Active, not recruiting
First Posted : March 15, 2019
Last Update Posted : September 15, 2022
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
EVOLVE 4.5/5.0 is a prospective, single-arm, multi-center observational (standard of care) trial intended to confirm the safety and effectiveness of the SYNERGY 4.50 mm and 5.00 mm Coronary Stent System for the treatment of patients with coronary artery disease in large vessels (≤ 28 mm in length, by visual estimate, in native coronary arteries > 4.00 mm to ≤5.00 mm in diameter, by visual estimate). This Post Approval study is a cohort associated with the SYNERGY MEGATRON Post Approval Study, which is registered under ClinicalTrials.gov ID: NCT04807439.

Condition or disease Intervention/treatment
Atherosclerosis Heart Diseases, Coronary Coronary Artery Disease Cardiovascular Diseases Device: SYNERGY 4.50 mm and 5.0 mm Coronary Stent System

Layout table for study information
Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A U.S. Post-Approval Study of the SYNERGY 4.50/5.00 mm Everolimus-Eluting Platinum Chromium Coronary Stent System (Evolve 4.5/5.0)
Actual Study Start Date : May 9, 2019
Actual Primary Completion Date : January 7, 2022
Estimated Study Completion Date : December 2023

Intervention Details:
  • Device: SYNERGY 4.50 mm and 5.0 mm Coronary Stent System
    The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).


Primary Outcome Measures :
  1. Target Lesion Failure (TLF) rate [ Time Frame: 12-months ]
    12-month Target Lesion Failure (TLF) rate, defined as any ischemia driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Eligible patients include those with atherosclerotic coronary lesions with vessel diameters that can appropriately be treated with 4.50 mm and/or 5.00 mm stents according to the commercially approved SYNERGY DFU
Criteria

Inclusion Criteria:

  • A patient is an acceptable candidate if they require treatment with a 4.50 or 5.00 mm SYNERGY stent for the treatment of their disease in accordance with the applicable guidelines on PCI, the SYNERGY DFU, and the Declaration of Helsinki.

Exclusion Criteria:

  • Planned treatment with a non-SYNERGY stent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03875651


Locations
Layout table for location information
United States, Connecticut
Yale New Haven Hospital
New Haven, Connecticut, United States, 06510
United States, Florida
Clearwater Cardiovascular Consultants
Clearwater, Florida, United States, 33756
United States, Massachusetts
Beth Israel Deaconness Medical Center
Boston, Massachusetts, United States, 02215
United States, Missouri
North Kansas City Hospital
Kansas City, Missouri, United States, 64116
United States, North Carolina
Wake Medical Center
Raleigh, North Carolina, United States, 27607
United States, Ohio
Lindner Center for Research and Education at Christ Hospital
Cincinnati, Ohio, United States, 45219
United States, Oregon
Oregon Health Science University
Portland, Oregon, United States, 97239
United States, Texas
Baylor Heart and Vascular Hospital
Dallas, Texas, United States, 75226
United States, Virginia
Inova Fairfax Hospital
Fairfax, Virginia, United States, 22042
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Layout table for investigator information
Principal Investigator: Robert C Stoler, MD Baylor Heart and Vascular Hospital
Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT03875651    
Other Study ID Numbers: S2357
First Posted: March 15, 2019    Key Record Dates
Last Update Posted: September 15, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy: (http://www.bostonscientific.com/en-US/data-sharing-requests.html).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Boston Scientific Corporation:
Drug-Eluting Stents
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Coronary Artery Disease
Coronary Disease
Heart Diseases
Atherosclerosis
Myocardial Ischemia
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases